Leerink Swann rated Outperform ATHERSYS INC (NASDAQ: ATHX) on 11/11/2008. Previously Leerink Swann rated Outperform ATHERSYS INC (NASDAQ: ATHX) on 09/17/2008., when the stock price was $2.27. Since then, ATHERSYS INC has lost 18.06% as of 05/21/2013's recent price of $1.86.
If you would have followed the previous Leerink Swann 's recommendation on ATHX, you would have lost 18.06% of your investment in 1707 days.

Athersys, Inc., is a biopharmaceutical company engaged in the discovery and development of therapeutic products. Through the application of its technologies, the Company has established a pipeline of therapeutic product development programs in multiple disease areas. The Company?s current product development portfolio consists of MultiStem, a patented and stem cell product that the Company is developing as a treatment for multiple disease indications, and that is being evaluated in two ongoing clinical trials. In addition, the Company are developing novel pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, narcolepsy or other forms of excessive daytime sleepiness. In December 2008, the Company were granted authorization by the United States Food and Drug Administration (FDA), to initiate a third clinical trial, administering MultiStem for the treatment of ischemic stroke.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.

Marked as spam